Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis
Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis
复制标题
DOI：
10.3109/14397595.2015.1129692
复制
发表时间：
2016-01-01
影响因子：
2.2
通讯作者：
Kawakami, Atsushi
中科院分区：
文献类型：
--
作者：
Iwamoto, Naoki;Fukui, Shoichi;Kawakami, Atsushi
目的：通过比较临床反应，评估从静脉内托珠单抗（TCZ）输注（TCZ-IV）到皮下注射TCZ-SC（TCZ-SC）的转换途径在现实世界中的疗效。方法：连续入选了58例类风湿关节炎（RA）患者，在2013年6月至2014年8月期间，TCZ-SC开始接受TCZ-IV治疗。在基线和从TCZ-IV转换为TCZ-SC 3个月后检查疾病活动评分（DAS）28-ESR、简化疾病活动指数（SDAI）和临床疾病活动指数（CDAI）。我们调查了体重和体重指数（BMI）是否影响TCZ-SC的疗效。结果：大多数患者在基线时达到缓解或低疾病活动度（77.6%，经DAS 28检查）。57例患者（98%）继续TCZ-SC治疗，3个月后疾病活动得到良好控制。高体重组（>= 60 kg）转换为TCZ-SC后，与体重
Objective: To evaluate the efficacy of switching the route from intravenous tocilizumab (TCZ) infusion (TCZ-IV) to subcutaneous TCZ injection (TCZ-SC) in a real-world setting through a comparison of the clinical response.Methods: Fifty-eight rheumatoid arthritis (RA) patients, for whom TCZ-SC was initiated following TCZ-IV between June 2013 and August 2014, were consecutively enrolled. Disease activity score (DAS) 28-ESR, simplified disease activity index (SDAI), and clinical disease activity index (CDAI) were examined at baseline and after switching from TCZ-IV to TCZ-SC for 3 months. We investigated whether body weight and body mass index (BMI) affected the efficacy of TCZ-SC.Results: Most of the patients had achieved remission or low disease activity at baseline (77.6% examined by DAS28). Fifty-seven patients (98%) continued the TCZ-SC treatment, and the disease activity was well controlled after 3 months. Delta DAS28 tended to be worsened after switching to TCZ-SC in the high-body-weight groups (>= 60 kg) as compared with the groups with body weight